Oxford, UK: 7 January 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy
company, announced today that it has signed a license agreement with the
Carnegie Institution of Washington and the University of Massachusetts Medical
School that grants the Company rights to key RNA interference (RNAi) technology
invented by Nobel Prize-winning scientists Andrew Z. Fire, PhD, and Craig C.
Mello, PhD. The rights granted are exclusive for RNAi gene silencing using
lentiviral vector technology for human gene therapy applications, including
Oxford BioMedica's proprietary LentiVector system. Under the terms of the
license agreement Oxford BioMedica will pay an upfront payment, milestone
payments and royalties on sales. These rights will run concurrently with the
rights of the existing licensees of the RNAi technology. Further details were
not disclosed.
